A promising aspect of producing anti-helminth vaccines is developing multivalent vaccines. In many cases the greatest protection from challenge is by vaccinating with a combination of Fasciola antigens [66, 67] . Therefore, based on the immunisation with FhGST-S1 showing an early response reducing hepatica damage, could be considered for inclusion into a multivalent vaccine against Fasciolosis. In addition, in light of our findings showing FhGST-S1 to be highly prominent in egg production and the egg itself, as with previous vaccination trials [67] , it will be important to investigate the ability of eggs voided from vaccinated animals to embryonate. The potential to reduce pasture contamination by inhibiting egg embryonation, combined with the www.plosntds.org demonstrated reduction in liver damage, warrants further exploration using rFhGST-S1 as a vaccine candidate.